Global DEB treatment market
The global DEB treatment market is experiencing significant growth, driven by advancements in gene and cell therapies. With the recent FDA approval of Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for recessive DEB, the landscape is evolving rapidly. For more details – https://www.reportprime.com/dystrophi